Reduced hematopoietic function and enhanced radiosensitivity of transforming growth factor-β1 transgenic mice

International Journal of Cancer

Volumn 90, Issue 1, 2000, Pages 13-21

  Vodovotz, Yoram ^a,d   Lucia, M Scott ^b   DeLucca, Anne Marie ^a   Mitchell, James B ^a   Kopp, Jeffrey B ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Hematopoiesis; Radiation; Transforming growth factor 1; Transgenic mice

Indexed keywords

CREATININE; TRANSFORMING GROWTH FACTOR BETA1;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; HEMATOCRIT; HEMATOPOIESIS; HISTOPATHOLOGY; LEUKOCYTE COUNT; LIVER; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY; SPLEEN; THROMBOCYTE COUNT; TRANSGENIC MOUSE; UREA NITROGEN BLOOD LEVEL; UREMIA; WHOLE BODY RADIATION;

EID: 0034688641     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000220)90:1<13::aid-ijc2>3.0.co;2-u     Document Type: Article

References (42)

1. Weichselbaum RR, Hallahan DE, Sukhatme V, et al. Biological consequences of gene regulation after ionizing radiation exposure. J Natl Cancer Inst 1991;83: 480-484.
2. McBride WH, Dougherty GJ. Radiotherapy for genes that cause cancer. Nat Med 1995;1:1215-1217.
3. Dalmau SR, Freitas CS, Savino W. Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines. Leuk Res 1997;21:93-99.
4. Roberts AB, Sporn MB. The transforming growth factor-betas. In: Sporn MB, Roberts AB, editors. Peptide growth factors and their receptors. Berlin: Springer-Verlag, 1990:419-472.
5. Massagué J. The transforming growth factor-β family. Annu Rev Cell Biol 1990;6:597-641.
6. Kimchi A. Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 1992;50:1-9.
7. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 1994;180:1587-1590.
8. McCartney-Francis N, Wahl SM. Transforming growth factor β: a matter of life and death. J Leukoc Biol 1994;55:401-409.
9. Ruscetti FW, Jacobsen SE, Birchenall-Roberts M, et al. Role of transforming growth factor-β1 in regulation of hematopoiesis. Ann NY Acad Sci 1991;628:31-43.
10. Keller JR, Jacobsen SE, Sill KT, et al. Stimulation of granulopoiesis by transforming factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc Natl Acad Sci USA 1991;88:7190-7194.
11. Sitnicka E, Ruscetti FW, Priestley GV, et al. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996;88:82-88.
12. Roberts AB, Sporn MB. Transforming growth factor-β. In: Clark RAF, editor. The molecular and cellular biology of wound repair. New York: Plenum Press. 1996: 275-308.
13. Suardet L, Little JP. Radio-induced modulation of transforming growth factor β1 sensitivity in p53 wild-type human colorectal-cancer cell line. Int J Cancer 1996;68:126-131.
14. Neta R, Oppenheim JJ. Schreiber RD, et al. Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance. J Exp Med 1991;173:1177-1182.
15. Flaumenhaft R, Kojima S, Abe M, et al. Activation of latent transforming growth factor β. Adv Pharmacol 1993;24:51-76.
16. Barcellos-Hoff MH. Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 1993;53:3880-3886.
17. Barcellos-Hoff MH, Derynck R, Tsang ML-S. et al. Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 1994;93:892-899.
18. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-β 1 expression in irradiated liver. Radiat Res 1990;122:77-85.
19. Anscher MS, Murase T, Prescott DM, et al. Changes in plasma TGF-β levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiation Oncology Biol Phys 1994;30:671-676.
20. Langberg CW, Hauer-Jensen M, Sung C-C, et al. Expression of fibrogenic cytokines in rat small intestine after fractionated irradiation. Radiother Oncol 1994;32: 29-36.
21. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
22. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995;92:2572-2576.
23. Böttinger EP, Factor VM, Tsang ML-S, et al. The recombinant proregion of transforming growth factor β1 (latency-associated peptide) inhibits active transforming growth factor β1 in transgenic mice. Proc Natl Acad Sci USA 1996;93:5877-5882.
24. Vodovotz Y, Kopp JB, Takeguchi H, et al. Increased mortality, blunted production of nitric oxide, and increased production of tumor necrosis factor-α in endotoxemic transforming growth factor-β1 transgenic mice. J Leukoc Biol 1998;63:31-39.
25. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
26. Abrams HL. Influence of age, body weight, and sex on susceptibility of mice to the lethal effects of X-radiation. Proc Soc Exp Biol Med 1951;76:729-732.
27. Hall EJ. Radiobiology for the radiologist. 3rd ed. Philadelphia: Lippincott, 1994.
28. Bursch W, Oberhammer F, Jirtle RL, et al. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis. Br J Cancer 1993;67:531-536.
29. Hsing AY, Kadomatsu K, Bonham MJ, et al. Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res 1996;56:5146-5149.
30. Vodovotz Y, Hsing A, Cook JA, et al. Qualitative and quantitative analysis of DNA fragmentation using digital imaging. Anal Biochem 1997;250:147-152.
31. Ehrhart EJ, Carroll A, Segarini P, et al. Latent transforming growth factor-β activation in situ: Quantitative and functional evidence after low dose irradiation. FASEB J 1997;11:991-1002.
32. Anscher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328: 1592-1598.
33. Chuncharunee S. Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo. Br J Haematol 1993;84:374-380.
34. Jansen R. Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil. J Immunol 1991;147: 3342-3347.
35. Grzegorzewski K. Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 1994;180:1047-1057.
36. Grainger DJ, Mosedale DE, Metcalfe JC, et al. Active and acid-activatable TGF-β in human sera, platelets, and plasma. Clin Chim Acta 1995;235:11-31.
37. Anscher MS, Kong F-M, Murase T, et al. Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ. Br J Radiol 1995;68:331-333.
38. 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155-162.
39. Murase T, Anscher MS, Petros WP, et al. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity. Bone Marrow Transpl 1995;15:173-178.
40. Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1995;1:74-79.
41. Letterio JJ, Roberts AB. Transforming growth factor-β1-deficient mice: identification of isoform-specific activities in vivo. J Leukoc Biol 1996;59:769-774.
42. Vodovotz Y. Control of nitric oxide production by transforming growth factor-β1 mechanistic insights and potential relevance to human disease. Nitric Oxide: Biol Chem 1997;1:3-17.